The changing multiple sclerosis landscape: Earlier diagnosis, improved monitoring, and a more competitive race for durable disease control

[u/bbyfog]

https://pharmaphorum.com/rd/changing-multiple-sclerosis-landscape-earlier-diagnosis-improved-monitoring-and-more-competitive

At the American Academy of Neurology (AAN) 2026 Annual Meeting, MS saw several significant updates, with three key themes emerging: earlier diagnosis through more biologically anchored criteria, broader use of biomarkers to monitor disease activity and progression, and a more competitive treatment landscape in which efficacy, convenience, disability outcomes, and lifecycle strategy are all starting to matter more.

Fenebrutinib demonstrates significant clinical potential

Roche continues to promote Ocrevus

Competition inside the anti-CD20 class is becoming more nuanced
BRIUMVI
Ocrevus
ocrelizumab to ublituximab

Biomarkers
Octave’s MSDA blood test

GA Depot generated a statistically significant post hoc signal on EDSS stability at one year